KALA BIO, Inc.

NasdaqCM:KALA Stock Report

Market Cap: US$31.2m

KALA BIO Past Earnings Performance

Past criteria checks 0/6

KALA BIO has been growing earnings at an average annual rate of 36.8%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 74% per year.

Key information

36.81%

Earnings growth rate

60.19%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-74.05%
Return on equity-182.64%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Oct 20

Kala Pharmaceuticals to execute reverse stock split

Kala Pharmaceuticals (NASDAQ:KALA) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s (KALA) issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. The split will reduce the number of shares of common stock outstanding from 73,208,140 shares to ~1,464,163 shares, subject to adjustment for the rounding up of fractional shares. The stock will will begin trading on a split-adjusted basis when the market opens on Friday, October 21, 2022. KALA shares are down over 2% premarket
Seeking Alpha • Aug 10

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.36 (+36.8% Y/Y) and the consensus Revenue Estimate is $2.02M (-33.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

Revenue & Expenses Breakdown

How KALA BIO makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:KALA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-202113
31 Dec 250-272419
30 Sep 250-361824
30 Jun 250-371823
31 Mar 250-361822
31 Dec 240-391822
30 Sep 240-391922
30 Jun 240-391922
31 Mar 240-402021
31 Dec 230-422119
30 Sep 230-462217
30 Jun 230-92617
31 Mar 233-264417
31 Dec 224-456518
30 Sep 226-808317
30 Jun 228-1379914
31 Mar 229-14510413
31 Dec 2111-14310512
30 Sep 2112-12610812
30 Jun 2111-12610613
31 Mar 219-1139316
31 Dec 206-1048118
30 Sep 205-956921
30 Jun 205-906025
31 Mar 206-916226
31 Dec 196-946527
30 Sep 195-986530
30 Jun 193-905830
31 Mar 191-814831
31 Dec 180-673529
30 Sep 180-532626
30 Jun 180-472026
31 Mar 180-441527
31 Dec 170-421129
30 Sep 170-39730
30 Jun 170-39631
31 Mar 170-38829
31 Dec 160-33825
30 Sep 160-30722
30 Jun 160-25816
31 Mar 160-18513
31 Dec 150-17511
30 Sep 150-174-2

Quality Earnings: KALA is currently unprofitable.

Growing Profit Margin: KALA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KALA is unprofitable, but has reduced losses over the past 5 years at a rate of 36.8% per year.

Accelerating Growth: Unable to compare KALA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KALA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: KALA has a negative Return on Equity (-182.64%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 18:15
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KALA BIO, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Biren AminJefferies LLC
Christopher NeyorJ.P. Morgan